ANIK - Anika Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Show:

Income Statement

Annual

All numbers in thousands

Revenue	12/31/2017	12/31/2016	12/31/2015	12/31/2014
Total Revenue	113,420	103,379	92,999	105,595
Cost of Revenue	27,364	24,027	21,053	20,930
Gross Profit	86,056	79,352	71,946	84,665
Operating Expenses
Research Development	18,787	10,732	8,290	8,144
Selling General and Administrative	21,540	18,013	14,825	15,074
Non Recurring	-	-	-	-
Others	-	-	-	-
Total Operating Expenses	67,691	52,772	44,168	44,148
Operating Income or Loss	45,729	50,607	48,831	61,447
Income from Continuing Operations
Total Other Income/Expenses Net	473	263	-577	58
Earnings Before Interest and Taxes	45,729	50,607	48,831	61,447
Interest Expense	-	-	-	-
Income Before Tax	46,202	50,870	48,254	61,505
Income Tax Expense	14,386	18,323	17,496	23,186
Minority Interest	-	-	-	-
Net Income From Continuing Ops	31,816	32,547	30,758	38,319
Non-recurring Events
Discontinued Operations	-	-	-	-
Extraordinary Items	-	-	-	-
Effect Of Accounting Changes	-	-	-	-
Other Items	-	-	-	-
Net Income
Net Income	31,816	32,547	30,758	38,319
Preferred Stock And Other Adjustments	-	-	-	-
Net Income Applicable To Common Shares	31,816	32,547	30,758	38,319